ABSTRACT
Extracellular vesicles (EVs) act as molecular mediators in the tumor microenvironment, by shuttling information contained within malignant cells and functioning as regulators of the immune system. Circular (circ)RNAs are characterized by a closed loop-like structure that makes them more stable in the extracellular milieu and suitable to be packaged inside EVs. circPVT1 (hsa_circ_0001821) showed an oncogenic role in several cancer types and immunosuppressive properties in myeloid and lymphoid cell subsets. In this study, we characterized EVs from acute myeloid leukemia (AML) patients in terms of size, concentrations, surface markers and circPVT1 cargo. We showed that circPVT1 is overexpressed by primary blast cells from newly-diagnosed AML patients compared with hematopoietic stem-progenitor cells and is released as cell-free RNA in the plasma. We isolated EVs from the plasma of AML patients and healthy subjects by size exclusion chromatography and characterized them by nanoparticle tracking analysis. EVs from patients' plasma are larger compared with those from healthy subjects and their surface profile is characterized by higher levels of the leukemic cell markers CD133, CD105, CD49e and other immune-related epitopes, with differences according to AML molecular profile. Moreover, digital PCR analysis revealed that circPVT1 is more abundant inside EVs from the plasma of AML patients compared with healthy subjects. Our findings provide new insights on the features and content of AML EVs and suggest a role of circPVT1 in the crosstalk between AML cells and the tumor microenvironment.
Subject(s)
Extracellular Vesicles , Leukemia, Myeloid, Acute , Humans , Leukemia, Myeloid, Acute/metabolism , Extracellular Vesicles/metabolism , RNA, Circular/genetics , RNA, Circular/metabolism , Hematopoietic Stem Cells/metabolism , Cell Communication , Tumor Microenvironment/geneticsABSTRACT
ß-thalassemia major (ßTM) patients require frequent blood transfusions, with consequences that span from allogenic reactions to iron overload. To minimize these effects, ßTM patients periodically receive leucodepleted packed red blood cells (P-RBCs) stored for maximum 14 days. The aim of this study was to compare two alternative routine procedures to prepare the optimal P-RBCs product, in order to identify differences in their content that may somehow affect patients' health and quality of life (QoL). In method 1, blood was leucodepleted and then separated to obtain P-RBCs, while in method 2 blood was separated and leucodepleted after removal of plasma and buffycoat. Forty blood donors were enrolled in two independent centers; couples of phenotypically matched whole blood units were pooled, divided in two identical bags and processed in parallel following the two methods. Biochemical properties, electrolytes and metabolic composition were tested after 2, 7 and 14 days of storage. Units prepared with both methods were confirmed to have all the requirements necessary for ßTM transfusion therapy. Nevertheless, RBCs count and Hb content were found to be higher in method-1, while P-RBCs obtained with method 2 contained less K+, iron and storage lesions markers. Based on these results, both methods should be tested in a clinical perspective study to determine a possible reduction of transfusion-related complications, improving the QoL of ßTM patients, which often need transfusions for the entire lifespan.
Subject(s)
Erythrocyte Transfusion , beta-Thalassemia/blood , beta-Thalassemia/therapy , Adult , Blood Platelets/metabolism , Blood Proteins/metabolism , Cytokines/metabolism , Electrolytes/metabolism , Erythrocytes/metabolism , Hemolysis , Humans , Iron/metabolism , L-Lactate Dehydrogenase/metabolism , Leukocytes/metabolism , Male , MetabolomeABSTRACT
BACKGROUND: The average hemoglobin content of red cell concentrates (RCC) varies depending on the method of preparation. Surprisingly less data are available concerning the clinical impact of those differences. STUDY DESIGN AND METHODS: The effects of two types of RCC (RCC-A, RCC-B) on transfusion regime were compared in a non-blinded, prospective, randomized, two-period, and crossover clinical trial. RCC-A was obtained by whole blood leukoreduction and subsequent plasma removal, RCC-B removing plasma and buffy coat first, followed by leukoreduction. Eligible patients were adult, with transfusion-dependent thalassemia (TDT). RESULTS: RCC-A contained 63.9 (60.3-67.8) grams of hemoglobin per unit (median with 1st and 3rd quartile), RCC-B 54.5 (51.0-58.2) g/unit. Fifty-one patients completed the study. With RCC-B, the average pre-transfusion hemoglobin concentration was 9.3 ± 0.5 g/dl (mean ± SD), the average transfusion interval 14.2 (13.7-16.3) days, the number of RCC units transfused per year 39.3 (35.4-47.3), and the transfusion power index (a composite index) 258 ± 49. With RCC-A, the average pre-transfusion hemoglobin concentration was 9.6 ± 0.5 g/dl (+2.7%, effect size 0.792), the average transfusion interval 14.8 (14.0-18.5) days (+4.1%, effect size 0.800), the number of RCC units transfused per year 34.8 (32.1-42.5) (-11.4%, effect size -1.609), and the transfusion power index 272 ± 61 (+14.1%, effect size 0.997). All differences were statistically highly significant (p < .00001). The frequency of transfusion reactions was 0.59% with RCC-A and 0.56% with RCC-B (p = 1.000). CONCLUSION: To reduce the number of RCC units consumed per year and the number of transfusion episodes, TDT patients should receive RCC with the highest average hemoglobin content.
Subject(s)
Erythrocyte Transfusion/methods , Hemoglobins/analysis , Thalassemia/therapy , Adult , Cross-Over Studies , Erythrocyte Transfusion/adverse effects , Erythrocytes/chemistry , Erythrocytes/cytology , Female , Humans , Leukocyte Reduction Procedures , Male , Middle Aged , Plasmapheresis , Prospective Studies , Thalassemia/blood , Transfusion Reaction/etiology , Treatment OutcomeABSTRACT
BACKGROUND AND OBJECTIVES: Growing health care demands, the uneven distribution of requirements for highly specialised services and the limits to the resources available to ensure an adequate response to the health care demands all make clear the managerial and macroeconomic need to adapt the organizational set-up of the health care facilities, redistributing the productive activities and care services in the territory, to meet the demands. We also found that it had become necessary to identify a different organizational model from the one in use in order to match the availability of platelet concentrates to the dynamics of the increased requests for this blood component in the setting of an Interhospital Immunotransfusion Department that involves the hospitals of Rimini, Forlì and Cesena. METHODS: Observational and statistical methods were used to determine the production, productivity, efficiency, efficacy and cost-benefit ratio of the production of platelet concentrates and the appropriateness, with respect to the dynamics and territorial distribution of the requests, before and after a profound procedural and methodological reorganisation which included centralisation of the production and the adoption of an automatic instrument for processing platelets from buffy-coats (OrbiSac System). RESULTS: The reorganization enabled the Department to reach almost complete self-sufficiency, to produce concentrates with a platelet content conforming with the indications of ministerial decrees, to uniform the quality of this blood component within the Department and to improve the use of human resources.